Charles E. Halstenson

1.8k total citations
53 papers, 1.3k citations indexed

About

Charles E. Halstenson is a scholar working on Pharmacology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Charles E. Halstenson has authored 53 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pharmacology, 12 papers in Pharmacology and 11 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Charles E. Halstenson's work include Antibiotics Pharmacokinetics and Efficacy (18 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Analytical Methods in Pharmaceuticals (9 papers). Charles E. Halstenson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (18 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Analytical Methods in Pharmaceuticals (9 papers). Charles E. Halstenson collaborates with scholars based in United States, Canada and Netherlands. Charles E. Halstenson's co-authors include Gary R. Matzke, William F. Keane, Paul A. Abraham, John A. Opsahl, Edward F. Foote, Louis J. Ling, Stephen W. Smith, David R. Luke, Allan J. Collins and J Sobota and has published in prestigious journals such as Kidney International, Antimicrobial Agents and Chemotherapy and The Journal of the Acoustical Society of America.

In The Last Decade

Charles E. Halstenson

53 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles E. Halstenson United States 22 374 254 250 232 163 53 1.3k
D. H. Lawson United Kingdom 22 177 0.5× 157 0.6× 221 0.9× 112 0.5× 140 0.9× 52 1.5k
John A. Opsahl United States 17 228 0.6× 121 0.5× 189 0.8× 84 0.4× 457 2.8× 48 1.1k
Paul A. Abraham United States 15 179 0.5× 110 0.4× 120 0.5× 254 1.1× 204 1.3× 34 854
Curtis A. Johnson United States 21 481 1.3× 140 0.6× 163 0.7× 299 1.3× 41 0.3× 68 1.3k
H.-H. Neumayer Germany 18 326 0.9× 126 0.5× 64 0.3× 102 0.4× 223 1.4× 43 1.3k
Thomas C. Dowling United States 23 371 1.0× 176 0.7× 144 0.6× 62 0.3× 396 2.4× 66 1.6k
Richard A. Robson New Zealand 29 348 0.9× 270 1.1× 330 1.3× 240 1.0× 225 1.4× 87 2.8k
Brian S. Decker United States 18 296 0.8× 520 2.0× 194 0.8× 85 0.4× 103 0.6× 44 1.6k
Stefan Russmann Switzerland 26 240 0.6× 208 0.8× 195 0.8× 82 0.4× 125 0.8× 64 2.2k
Amy Barton Pai United States 19 332 0.9× 134 0.5× 119 0.5× 287 1.2× 116 0.7× 54 1.2k

Countries citing papers authored by Charles E. Halstenson

Since Specialization
Citations

This map shows the geographic impact of Charles E. Halstenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles E. Halstenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles E. Halstenson more than expected).

Fields of papers citing papers by Charles E. Halstenson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles E. Halstenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles E. Halstenson. The network helps show where Charles E. Halstenson may publish in the future.

Co-authorship network of co-authors of Charles E. Halstenson

This figure shows the co-authorship network connecting the top 25 collaborators of Charles E. Halstenson. A scholar is included among the top collaborators of Charles E. Halstenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles E. Halstenson. Charles E. Halstenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Browne, Susan, et al.. (2001). The Influence of Food on the Bioavailability of a Twice‐Daily Controlled Release Carbamazepine Formulation. The Journal of Clinical Pharmacology. 41(2). 183–186. 22 indexed citations
2.
Swan, Suzanne K., Charles E. Halstenson, Bertram L. Kasiske, & Allan J. Collins. (1996). Determination of residual renal function with iohexol clearance in hemodialysis patients. Kidney International. 49(1). 232–235. 33 indexed citations
3.
Foote, Edward F., et al.. (1995). Disposition of Misoprostol and its Active Metabolite in Patients With Normal and Impaired Renal Function. The Journal of Clinical Pharmacology. 35(4). 384–389. 27 indexed citations
4.
Swan, Suzanne K., et al.. (1995). Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. American Journal of Kidney Diseases. 26(6). 918–923. 40 indexed citations
5.
Foote, Edward F., et al.. (1995). The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. American Journal of Kidney Diseases. 25(3). 420–425. 26 indexed citations
6.
Awni, Walid M., et al.. (1994). A Dose‐Ranging Pharmacokinetics Study of Sodium Diethyldithiocarbamate in Normal Healthy Volunteers. The Journal of Clinical Pharmacology. 34(12). 1183–1190. 11 indexed citations
7.
8.
Thompson, Gary A., Michael T. Kenny, Eric Lewis, et al.. (1992). Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30MGKG−1. Biopharmaceutics & Drug Disposition. 13(8). 571–581. 5 indexed citations
9.
Johnson, Curtis A., Charles E. Halstenson, J S Kelloway, et al.. (1992). Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clinical Pharmacology & Therapeutics. 51(1). 32–41. 55 indexed citations
10.
Peter, Wendy L. St., et al.. (1992). Clinical Pharmacokinetics of Antibiotics in Patients with Impaired Renal Function. Clinical Pharmacokinetics. 22(3). 169–210. 35 indexed citations
11.
Halstenson, Charles E., et al.. (1992). The Pharmacokinetics of Quinapril and Its Active Metabolite, Quinaprilat, in Patients with Various Degrees of Renal Function. The Journal of Clinical Pharmacology. 32(4). 344–350. 8 indexed citations
12.
Halstenson, Charles E., et al.. (1991). Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology & Therapeutics. 50(6). 702–712. 141 indexed citations
13.
Matzke, Gary R., Charles E. Halstenson, John A. Opsahl, et al.. (1990). Pharmacokinetics of Loratadine in Patients with Renal Insufficiency. The Journal of Clinical Pharmacology. 30(4). 364–371. 16 indexed citations
14.
Kasiske, B L, et al.. (1990). The Effects of Lovastatin in Hyperlipidemic Patients With the Nephrotic Syndrome. American Journal of Kidney Diseases. 15(1). 8–15. 38 indexed citations
15.
Abraham, Paul A., et al.. (1990). Renal Function during Erythropoietin Therapy for Anemia in Predialysis Chronic Renal Failure Patients. American Journal of Nephrology. 10(2). 128–136. 33 indexed citations
16.
Guay, David R.P., Walid M. Awni, John W. A. Findlay, et al.. (1988). Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clinical Pharmacology & Therapeutics. 43(1). 63–71. 58 indexed citations
17.
Abraham, Paul A., Charles E. Halstenson, John A. Opsahl, Gary R. Matzke, & William F. Keane. (1988). Suprofen-Induced Uricosuria. American Journal of Nephrology. 8(2). 90–95. 7 indexed citations
18.
Halstenson, Charles E., Paul A. Abraham, John A. Opsahl, et al.. (1987). Disposition of Famotidine in Renal Insufficiency. The Journal of Clinical Pharmacology. 27(10). 782–787. 23 indexed citations
19.
Matzke, Gary R., et al.. (1987). Gentamicin Disposition in Young and Elderly Patients with Various Degrees of Renal Function. The Journal of Clinical Pharmacology. 27(3). 216–220. 21 indexed citations
20.
Guay, David R.P., et al.. (1987). Influence of Gender on the Disposition of Cefotaxime and Desacetylcefotaxime. Therapeutic Drug Monitoring. 9(3). 259–262. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. H. Lawson Breakdown of academic impact, for papers by John A. Opsahl Breakdown of academic impact, for papers by Paul A. Abraham Breakdown of academic impact, for papers by Curtis A. Johnson Breakdown of academic impact, for papers by H.-H. Neumayer Breakdown of academic impact, for papers by Thomas C. Dowling Breakdown of academic impact, for papers by Richard A. Robson Breakdown of academic impact, for papers by Brian S. Decker Breakdown of academic impact, for papers by Stefan Russmann Breakdown of academic impact, for papers by Amy Barton Pai
Rankless by CCL
2026